Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulumtatug Furvedotin in Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06908928Phase 1Recruiting
- Sponsor
- Mabwell
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bulumtatug fuvedotin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Mabwell. Primary endpoint: Objective Response Rate. Started Aug 2025; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06908928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908928.